0
Special Report |

Inhaled Fluticasone Propionate by Diskus in the Treatment of Asthma*: A Comparison of the Efficacy of the Same Nominal Dose Given Either Once or Twice a Day

Mary E. Purucker; Curtis J. Rosebraugh; Feng Zhou; Robert J. Meyer
Author and Funding Information

*From the Division of Pulmonary and Allergy Drug Products (Drs. Purucker and Rosebraugh), the Division of Biometrics (Dr. Zhou), and the Office of Drug Evaluation II (Dr. Meyer), Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD.

Correspondence to: Curtis J. Rosebraugh, MD, MPH, Division of Over The Counter Drug Products 5600 Fisher Ln, HFD-560 Rockville, MD 20857; email: RosebraughC@cder.fda.gov



Chest. 2003;124(4):1584-1593. doi:10.1378/chest.124.4.1584
Text Size: A A A
Published online

Study objective: In September 2000, the US Food and Drug Administration (FDA) approved the use of Flovent Diskus (FD) [fluticasone propionate; GlaxoSmithKline; Research Triangle Park, NC], which is an orally inhaled, dry-powder corticosteroid, for the maintenance treatment of asthma at dosages of 50 to 1,000 μg administered twice-daily. Once-daily dosage regimens did not receive approval. This article will detail six clinical trials, five of which incorporated comparative once-daily and twice-daily treatment arms of the same nominal dose of FD.

Design: Six 12-week, randomized, double-blind, placebo-controlled studies in patients with mild-to-moderate asthma, including two pediatric asthma trials (patient age, 4 to 11 years) of total daily doses of fluticasone propionate (FP) of 100 or 200 μg, and four adult and adolescent studies of total daily doses of FP of 100, 200, or 500 μg.

Results: Twice-daily dosing was numerically superior to once-daily dosing at the same nominal dose in all comparative studies for the primary end point, change in predose FEV1. In five trials, the results of the once-daily dosage of FP were statistically indistinguishable from those with placebo. One trial demonstrated the superiority of FP, 500 μg once-daily, over placebo; however, the effect size was half that observed with twice-daily dosing. Once-daily FP dosing showed no advantage in safety or in patient adherence to medication.

Conclusions: In the FDA review of once-daily dosing of the FD regimen, 100 or 200 μg once-daily dosing was not shown to be significantly better than placebo. FP 500 μg once-daily was found to be superior to placebo, but at about one half the effect size as the same nominal dose given bid. No advantage in patient safety or adherence was demonstrated for once-daily administration over twice-daily administration, and once-daily administration is not currently recommended.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
Asthma in pregnancy.
American College of Obstetricians and Gynecologists | 9/19/2008
Adapting your practice: treatment and recommendations for homeless patients with asthma.
National Health Care for the Homeless Council, Inc. | 6/13/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543